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Somatic mutations contribute to tumorigenesis. Although these mutations occur in all pro-
liferating cells, their accumulation under non-malignant conditions, such as in autoimmune
disorders, has not been investigated. Here, we show that patients with newly diagnosed
rheumatoid arthritis have expanded CD8þ T-cell clones; in 20% (5/25) of patients CD8þ T
cells, but not CD4þ T cells, harbour somatic mutations. In healthy controls (n¼ 20), only
one mutation is identiﬁed in the CD8þ T-cell pool. Mutations exist exclusively in the
expanded CD8þ effector-memory subset, persist during follow-up, and are predicted to
change protein functions. Some of the mutated genes (SLAMF6, IRF1) have previously
been associated with autoimmunity. RNA sequencing of mutation-harbouring cells shows
signatures corresponding to cell proliferation. Our data provide evidence of accumulation of
somatic mutations in expanded CD8þ T cells, which may have pathogenic signiﬁcance for
RA and other autoimmune diseases.
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T
cells undergo clonal expansion after they recognize
cognate antigens, which are presented by professional
antigen-presenting cells. Because the mutation rate in
lymphoid precursors has been estimated to be B10 6 per cell
division, errors in DNA replication are likely to accumulate
during cell divisions1,2. Somatic mutations have a critical
function in cancer pathogenesis, and mutations derived from
haematopoietic stem cells and progenitor cells have also been
detected in peripheral-blood cells. This phenomenon is called
clonal haematopoiesis3–7. The occurrence of somatic mutations in
mature, clonally expanded, non-malignant T-cell populations has
not been fully investigated, nor have their effects on the disease
process and clonal properties been determined.
Rheumatoid arthritis (RA) is a common systemic inﬂamma-
tory disease of autoimmune origin8, characterized by chronic
inﬂammation9, and T-cell-mediated autoantibody production
occurring years before the clinical diagnosis10–12. RA often
co-manifests in patients with large granular lymphocyte (LGL)
leukaemia, a rare lymphoproliferative disorder in which we
recently discovered that expanded CD8þ T-cell clones harbour
somatic STAT3 mutations13. Interestingly, LGL leukaemia
patients with multiple STAT3 mutations have a higher
incidence of RA (43%) than patients without STAT3 mutations
(6%)14, thus raising the possibility that patients with STAT3-
mutated LGL leukaemia and clonal-lymphocyte proliferation are
at a greater risk of developing a non-malignant autoimmune
disease and that CD8þ T-cell clones carrying somatic mutations
may participate in the autoimmune process. Alternatively,
autoimmune diseases may facilitate the acquisition of somatic
mutations in lymphocytes.
In this study, we investigate whether T cells in people with a
non-malignant autoimmune disorder without known lympho-
proliferation harbour somatic mutations and analyse blood
samples from individuals with newly diagnosed, untreated RA.
With a ﬂow-cytometry-based T-cell clonality screen we identify
potential clonal expansions in the CD8þ T cells and conﬁrm the
ﬁndings using deep T-cell receptor b chain (TCRB) sequencing.
We discover somatic mutations in puriﬁed CD8þ T cells with a
custom deep-sequencing panel including 986 immune-related
genes and with exome and deep amplicon sequencing.
These results provide a link between cancerous processes and
autoimmunity.
Results
The clonality of CD8þ T cells increases with age. We collected
blood samples from 82 untreated newly diagnosed ACR/EULAR
2010 criteria-fulﬁlling RA patients and 20 healthy controls after
obtaining written informed consent (Fig. 1a). T-cell clonality was
initially screened with a ﬂow-cytometry-based assay using a panel
of TCR Vb-speciﬁc antibodies. This method allows for rapid
and robust analysis of TCRB V-gene usage and facilitates ﬂow-
cytometry-based cell sorting of the populations of interest.
To assess the clonality in more detail (a T-cell clone is deﬁned by
a unique TCR b complementarity-determining region 3 [CDR3]
sequence), the samples were subjected to a next-generation
sequencing (NGS)-based TCR b (TCRB CDR3) deep-sequencing
assay.
Flow cytometry screening indicated increased clonality in
CD8þ T cells compared with CD4þ T cells (Supplementary
Fig. 1). Next, sorted CD8þ fractions were subjected to NGS
TCRB sequencing. The CD8þ V-gene usage in ﬂow cytometry
and TCRB-sequencing correlated well (Fig. 1b; Po0.0001,
Spearman correlation coefﬁcient r¼ 0.61), thus justifying the
use of ﬂow cytometry as a screening and sorting method.
Deep TCRB sequencing showed that in RA patients, the
clonality of CD8þ T cells (measured as the productive clonality
index) did not signiﬁcantly differ from that in age-matched
healthy controls (Fig. 1c). Interestingly, in patients, but not in
healthy controls, the clonality increased with age (Fig. 1d;
Po0.0001, Spearman correlation coefﬁcient r¼ 0.49; Supplementary
Fig. 2).
A proportion of RA patients harboured prominent CD8þ
T-cell clones. In 8/65 patients the largest clone composed over
20% of the total CD8þ cells, and in one individual patient (Pt 3)
the largest clone composed 51% of the total CD8þ lymphocyte
pool (Table 1, Fig. 1e). In the healthy controls, we identiﬁed only
two individual CD8þ clones that exceeded 20% of the total
CD8þ cells (Fig. 1e), whereas the largest clone in healthy
controls accounted for 26% (Table 1). In addition to clone size,
the V-gene usage distribution of clones composing over 1% of the
CD8þ cells was compared between the healthy controls and RA
patients. Only TCRBV07 was slightly overrepresented in the
healthy controls, and no differences were observed in other V
genes (Fig. 1f,g). RA patients’ TCRB amino-acid sequences were
not shared among CD8þ clones larger than 1%, with some
exceptions (Supplementary Table 1).
The CD8þ T-cell clonality was correlated with clinical
parameters (Table 1 and Supplementary Table 2) to discover
possible associations (Supplementary Figs 3 and 4). The
CD4/CD8-ratio (Spearman correlation coefﬁcient r¼  0.52),
the number of swollen joints (Spearman r¼  0.41) and
haemoglobin level (Spearman r¼  0.26) were each statistically
signiﬁcantly correlated with the CD8þ T-cell clonality.
From two patients (6 and 23, Table 1), paired synovial ﬂuid
and peripheral-blood samples were available. Several identical
CD8þ TCRB sequences were detected in the peripheral blood
and synovial ﬂuid (Supplementary Fig. 5).
HLA-A, -B, -C and –DRB1 haplotyping was performed on
65 patients and 20 controls (Supplementary Table 3). The
HLA-DRB1 allele frequencies demonstrated that our RA patients
shared the genetic characteristics typical of RA: the shared
epitope15 (RA risk allele) frequencies were higher in RA patients
than in healthy controls (Supplementary Fig 6; Fisher’s test
P¼ 0.03, OR 2.32). HLA-I allele frequencies did not differ
between the patients and the controls (Supplementary Fig. 7).
Further, when the patients were divided into two groups on the
basis of the median clonality index (high versus low clonality), no
statistically signiﬁcant differences were observed in shared
epitope or HLA-I allele frequencies.
Somatic mutations are identiﬁed in CD8þ cells. After
analysing T-cell clonality, we assessed whether somatic mutations
existed in puriﬁed CD8þ and/or CD4þ cells (Fig. 1a). We
designed a custom-sequencing panel of 986 immune-related
genes (Fig. 1a; a list of sequenced genes is presented in
Supplementary Table 4) to achieve greater sequencing depth
(500–1,000 ) than exome sequencing (50–100 ). This
methodology enabled us to detect mutations with lower variant
allele frequencies (VAFs).
Immunogene panel sequencing was performed on sorted
CD8þ and CD4þ cells from 25 patients (median age 61, range
19–75) and 20 healthy controls (median age 55, range 21–70). For
one patient (Pt 23, Table 1), the sequencing assay was performed
using CD4þ and CD8þ cells isolated from synovial ﬂuid.
A robust and veriﬁed variant-calling bioinformatics pipeline was
used for mutation calling13. Each patient’s own CD8þ cells were
compared with his/her own CD4þ cells, and a list of variants
occurring only in CD8þ (and not in CD4þ ) was obtained.
Thus, variants identiﬁed in both cell fractions were excluded from
further analyses. This approach allowed for exclusion of germline
variants and variants occurring in haematopoietic progenitor
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Figure 1 | Clonal expansions of CD8þ Tcells occur in RA patients and clonality increases with age. (a) The study workﬂow, presented as a ﬂow chart.
(b) The V-gene usage of the largest ﬂow-antibody-stained population correlated well with the corresponding V-gene usage in TCRB sequencing. The
comparison was performed using the 61 patients for whom both ﬂow cytometry and TCRB-sequencing data were available. Correlation was tested with
Spearman correlation. (c) CD8þ clonality index calculated on the basis of TCRB sequencing was compared between patients (n¼ 65) and healthy controls
(HC, n¼ 20) with the Mann–Whitney test, but there was no statistically signiﬁcant difference. The horizontal line represents the group median, and error
bars interquartile range (IQR). (d) The CD8þ TCRB-sequencing-based clonality index increases with age in RA patients (tested with Spearman correlation,
n¼ 65). (e) The percentage of patients and controls harbouring at least one CD8þ clone larger than 1%, 5%, 10%, and 20% of CD8þ is shown. (f) The
V-gene usage in CD8þ clones comprising over 1% of all CD8þ in patients and controls is shown. The data were obtained via TCRB sequencing, and are
presented as the number of clones using the denoted TCRBV gene adjusted for the number of individuals (RA¼65, HC¼ 20). (g) Odds ratios for CD8þ
clones comprising over 1% of CD8þ for each TCRBV gene. The error bars represent 95% conﬁdence intervals (CI), the arrow showing that the upper limit
does not ﬁt the scale. There were no differences between patients and controls (tested with Fisher’s test), except for TRBV07, which may be slightly
underrepresented in patients compared with controls (Fisher’s test, P¼0.00664, not adjusted for multiple comparisons, error bars 95% CI).
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cells. After comparing CD8þ to CD4þ , we repeated the
opposite comparison, using CD8þ as a control sample.
Median target coverage for the panel was 397 for CD4þ and
386 for CD8þ cells in RA patients, and 465 and 437 in healthy
controls, respectively (Supplementary Table 5). All putative
candidate variants were conﬁrmed with targeted amplicon
sequencing, a method with a sensitivity of 0.5% (ref. 14). A list
of the putative variants is included as Supplementary Data 1.
Amplicon-sequencing enabled us to conﬁrm nine somatic
variants occurring exclusively in CD8þ cells from four
individual RA patients and one variant in one healthy control
(Fig. 2a, Table 2, Supplementary Table 6 and Supplementary
Fig. 8a–c).
To discover mutations in genes that were not included in the
targeted immunogene panel, we performed exome sequencing on
ﬂow-sorted CD8þ lymphocytes from 3 RA patients. The subjects
Table 1 | Clinical characteristics of patients and healthy controls sequenced with immunogene panel sequencing.
Patient ID Sex Age at diagnosis Seropositive DAS28 Shared
epitope
Clonality Largest CD8þ
clone (%)
1 M 75 Yes 3.5 Yes/no 0.63 33.9
2 F 72 Yes 3.5 Yes/yes 0.28 7.8
3 M 44 Yes NA Yes/no 0.60 51.0
4 F 74 No NA No/no 0.24 13.2
5 F 59 Yes NA No/no 0.44 29.0
6 M 75 Yes 4.0 Yes/yes 0.41 11.1
7 M 66 Yes 3.9 No/no 0.35 13.8
8 F 61 Yes 3.1 No/no 0.08 2.0
9 M 45 Yes 4.0 Yes/no 0.28 17.2
10 M 69 Yes 3.3 Yes/no 0.46 16.2
11 F 52 Yes 2.1 Yes/no 0.43 27.5
12 M 51 Yes 3.6 Yes/yes 0.38 15.7
13 F 66 Yes 2.8 Yes/no 0.27 9.2
14 F 74 Yes 4.5 Yes/no 0.20 8.0
15 F 25 No 4.8 Yes/yes 0.15 4.5
16 F 62 Yes 4.2 Yes/yes 0.30 6.8
17 F 71 No 6.0 Yes/no 0.39 20.3
18 F 65 Yes 4.5 Yes/yes 0.28 10.2
19 F 58 Yes 5.2 No/no 0.17 8.0
20 F 46 Yes 2.1 Yes/no 0.37 16.2
21 F 48 No 5.0 No/no 0.11 3.0
22 F 68 Yes 1.9 No/no 0.21 7.0
23 F 24 No 4.2 NA 0.13 5.8
24 F 57 No 4.7 No/no 0.18 5.3
25 M 19 Yes 3.8 Yes/yes 0.09 4.2
Of 25 RA patients 68% F, 32% M median 61
(19–75)
76% seropositive Median 4.0
(1.9–6.0)
Median 0.28
(0.08–0.63)
Median 10.2
(2.0–51.0)
Of all RA patients 80% F, 20% M median 55
(19–82)
79% seropositive Median 4.0
(1.1–7.1)
Median 0.20
(0.033–0.63)
Median 6.7
(0.8–51.0)
HC1 F 58 NA NA Yes/no 0.38 11.8
HC2 M 61 NA NA Yes/yes 0.09 0.8
HC3 F 50 NA NA No/no 0.36 26.0
HC4 M 58 NA NA No/no 0.26 5.4
HC5 F 65 NA NA Yes/no 0.35 24.7
HC6 F 50 NA NA No/no 0.24 4.1
HC7 F 62 NA NA Yes/no 0.23 4.4
HC8 F 44 NA NA Yes/no 0.12 2.7
HC9 M 55 NA NA No/no 0.18 3.0
HC10 M 52 NA NA Yes/yes 0.08 1.7
HC11 M 48 NA NA No/no 0.04 0.6
HC12 F 57 NA NA Yes/no 0.15 6.2
HC13 F 56 NA NA Yes/no 0.13 4.6
HC14 M 70 NA NA Yes/no 0.17 2.4
HC15 F 47 NA NA No/no 0.30 7.1
HC16 M 48 NA NA Yes/no 0.18 11.1
HC17 F 21 NA NA Yes/no 0.08 7.1
HC18 M 60 NA NA No/no 0.38 12.0
HC19 M 43 NA NA Yes/no 0.38 17.5
HC20 F 66 NA NA Yes/no 0.26 7.1
Of HC 55% F, 45% M Median 56
(21–70)
Median 0.20
(0.043–0.39)
Median 5.8
(0.6-26.0)
DAS28, disease activity index in 28 joints; F, female; M, male; NA, not available; SE, shared epitope.
Immunogene panel sequencing was performed on both CD4þ and CD8þ cells of 25 newly diagnosed RA patients and 20 healthy controls (HCs), and the clinical characteristics are presented in the
table. More detailed clinical information is presented in Supplementary Table 2. Summarized data are presented for all 82 newly diagnosed RA patients, for the 25 patients sequenced with the
immunogene panel, and for the healthy controls. The results are presented as median values (range in parenthesis), if applicable. HLA-DRB1 alleles that predispose to seropositive RA, namely,
HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*10 and HLA-DRB1*14:02; Clonality, productive clonality index based on TCRB sequencing; Largest CD8þ clone, the largest productive T-cell clone size, shown
as percentage of all CD8þ ). For the shared epitope, data are presented showing the shared epitope status of both alleles (yes/yes, both DRB1 alleles were SE; yes/no, only one DRB1 allele was SE; no/no,
neither DRB1 allele was SE).
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were selected on the basis of the initial ﬂow-cytometry-based
clonality screen, and they all harboured exceptionally large cell
populations that were stained by a speciﬁc Vb family antibody.
A unique Vb chain-speciﬁc antibody stained 44–55% of the
total CD8þ lymphocyte pool, depending on the patient. The
sequencing data from the sorted CD8þ Vb-enriched lymphocyte
pool were compared with those from the polyclonal CD4þ
T-cell pool (germline control). Exome sequencing followed by
conﬁrmative amplicon sequencing revealed 24 novel somatic
mutations (Fig. 2a, Supplementary Table 6, Supplementary
Fig. 8d–f and Table 2) in the sorted CD8þ T-cell fractions. All
putative variants are included in Supplementary Data 1. The
exome-sequencing results were concordant with the immunogene
panel sequencing regarding the genes that were included in
the panel.
In total, we identiﬁed 30 novel somatic mutations in CD8þ
cells of ﬁve RA patients. In contrast, only one healthy control
harboured a single mutation in CD8þ cells. Immunopanel deep
sequencing identiﬁed mainly immunity-associated genes, whereas
exome sequencing added to the analysis by revealing somatic
variants in proliferation-associated and unclassiﬁed genes (Fig. 2a).
The identiﬁed mutations were classiﬁed into non-synonymous
(missense) coding- (81%), nonsense- (6%), frameshift- (10%) and
splice-site acceptor mutations (3%; Fig. 2b). Silent mutations were
excluded from the bioinformatics pipeline analysis. Table 2
reports scores predicting the effect of each mutation on the
protein, on the basis of amino-acid conservation and structural
information (SIFT; http://sift.jcvi.org/16–20 and Polyphen-2;
http://genetics.bwh.harvard.edu/pph2/21). Of the non-synonymous
mutations, 32% (8/25) were predicted to be probably damaging by
both Polyphen-2 and SIFT. All identiﬁed mutations were also
queried against the Catalogue of somatic mutations in cancer
(COSMIC, http://cancer.sanger.ac.uk/cosmic)22 database, and four
of the identiﬁed mutations have been reported in cancer
(Supplementary Table 7).
Somatic mutations are restricted to the expanded CD8þ clones.
Patient 1 was a 74-year-old male with palindromic rheumatism
(a subtype of RA with sudden attacks of joint pain and swelling).
At diagnosis, the ﬂow-cytometry screen detected a CD8þ
Vb13.1þ T-cell population composing 50.4% of total CD8þ T
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Figure 2 | Somatic mutations are detected in 5 patients and in 1 healthy control. (a) Somatic mutations were discovered in newly diagnosed RA patients
and in one healthy (HC) by using the immunogene panel (presented on the left side), and exome sequencing (presented on the right side of the ﬁgure).
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shown as percentage of all identiﬁed mutations. Silent mutations were excluded from the bioinformatics analysis.
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cells (Supplementary Fig. 9). TCRB deep sequencing revealed two
large (34% and 31%) T-cell clones (Fig. 3a). These two clones
remained stable during follow-up despite immunosuppressive
therapy with methotrexate, hydroxychloroquine and sulfasalazine
(Fig. 3b). Immunogene panel sequencing revealed mutations in
the PADI4, PROM1, C5, and CLIP2 genes, and exome-sequencing
additional mutations in 10 genes (Fig. 2a). Interestingly, one
nonsense mutation was detected in the PTPRO gene, which is
known to downregulate STAT3 activity, and phosphoﬂow
analysis indicated an exceptionally high amount (20–29%)
of phospho-STAT3-positive CD8þ T cells in this patient
(Supplementary Fig. 11). Amplicon sequencing of sorted CD8þ
Vb13.1þ and CD8þ T cells not expressing Vb13.1 conﬁrmed
that the mutations existed exclusively in the expanded CD8þ
Vb13.1þ population (Fig. 3c).
Patient 2 was a 72-year-old female who also had palindromic
rheumatism and a previous history of other inﬂammatory
disorders: asthma, lichen ruber and atrophic gastritis. At the
time of RA diagnosis, ﬂow cytometric screening identiﬁed two
unusually large populations of CD8þ T cells: Vb1þ (14%) and
Vb13.6þ (11%) (Supplementary Fig. 9). In deep TCRB
sequencing, the corresponding clones composed 4.6% and 7.8%
of CD8þ cells. The sums of speciﬁc V–J recombinations are
presented for CD8þ (Fig. 3d) and for sorted Vb1þ -stained
fractions (Fig. 3e). These clones remained stable during immuno-
suppressive treatment (methotrexate, hydroxychloroquine,
sulfasalazine) (Fig. 3f). Immunogene panel sequencing identiﬁed
three mutations (IRF1, SLAMF6, SEC14L3) in the patient’s
CD8þ cells (Fig. 2a). Cell sorting and amplicon sequencing from
a follow-up sample conﬁrmed that the discovered mutations were
restricted to the CD8þVb1þ population (Fig. 3g). In hetero-
zygous mutations, the mutation’s VAF is expected to be half of
the clone size if the mutation occurs in all of the clone’s cells. The
VAFs of IRF1 and SEC14L3 mutations (30–32%) in the sorted
CD8þVb1þ cells matched well with the clone size: TCRB
sequencing conﬁrmed that the ﬂow-sorted CD8þVb1þ cells
harboured a monoclonal 73% TRBV09-01 expansion, as deﬁned
by a unique nucleotide sequence.
Table 2 | Effects of the discovered mutations on the structure and function of affected proteins as determined by bioinformatic
prediction tools.
Patient Cell fraction Ref Var Gene Effect Exon Transcript AA change SIFT Poly Phen Var freq (%)
Immunopanel
1 CD8þ G A PADI4 NS 10 ENST00000375448 A359T 0.01 0.91 17.5
1 CD8þ T A PROM1 NS 4 ENST00000447510 N344Y 0.01 0.96 13.3
1 CD8þ A T C5 NS 9 ENST00000223642 C1532S 0.01 0.97 6.6
1 CD8þ *) G CLIP2 SSA - ENST00000223398 – NA NA 5.5
2 CD8þ C T IRF1 NS 8 ENST00000245414 G231E 0.29 0.04 6.5
2 CD8þ C T SEC14L3 STOP 4 ENST00000215812 W74* NA NA 6.4
2 CD8þ A C SLAMF6 NS 4 ENST00000368057 F238C 0.21 0.00 5.0
4 CD8þ GT G BST1 FS 7 ENST00000382346 F220fs NA NA 8.3
5 CD8þ C T CLEC10A NS 8 ENST00000254868 A235T 0.23 0.08 10.2
HC5 CD8þ T C CLU NS 1 ENST00000560366 H26R **) **) 13.9
Exome sequencing
1 CD8þVb13.1þ C T RP11-766F14.2.1 NS 1 ENST00000511828 R1077H 0.01 0.99 35.5
1 CD8þVb13.1þ A T PTPRO NS 11 ENST00000281171 M665L 0.18 0.17 32.4
1 CD8þVb13.1þ T A PROM1 NS 9 ENST00000447510 N344Y 0.04 0.96 28.0
1 CD8þVb13.1þ G A CNTN2 NS 17 ENST00000331830 G725R 0.33 0.51 28.0
1 CD8þVb13.1þ A AG SKP1 FS 5 ENST00000517625 E73fs NA NA 25.0
1 CD8þVb13.1þ C T GRM5 NS 4 ENST00000418177 V313M 0.00 1.00 21.3
1 CD8þVb13.1þ C T CRYBB2 NS 6 ENST00000398215 R160C 0.01 0.38 18.0
1 CD8þVb13.1þ A T MREG NS 5 ENST00000236976 F183I 0.12 0.60 15.8
1 CD8þVb13.1þ G A CDK12 NS 2 ENST00000447079 G499E 0.40 0.35 13.0
1 CD8þVb13.1þ A T C5 NS 38 ENST00000223642 C1532S 0.01 0.97 10.6
1 CD8þVb13.1þ C G TPTE NS 23 ENST00000361285 E504Q 1.00 0.03 10.2
1 CD8þVb13.1þ C T KIF16B NS 19 ENST00000408042 E689K 0.06 0.86 9.3
1 CD8þVb13.1 G A PADI4***) NS 10 ENST00000375448 A359T 0.01 0.91 20.0
3 CD8þVb7.2þ C A ADCY10 NS 23 ENST00000367851 M1103I 0.19 0.15 24.8
3 CD8þVb7.2þ T G SMARCAD1 NS 20 ENST00000359052 L851W 0.00 0.98 12.9
3 CD8þVb7.2þ T C PLRG1 NS 3 ENST00000393905 Q71R 0.57 0.00 7.2
4 CD8þVb1þ T C SCAF4 NS 20 ENST00000286835 Q966R 0.61 0.00 31.8
4 CD8þVb1þ GT G BST1 FS 7 ENST00000382346 F220fs NA NA 30.6
4 CD8þVb1þ G A STARD5 STOP 3 ENST00000302824 Q90* NA NA 27.6
4 CD8þVb1þ C T CLSPN NS 20 ENST00000318121 G1131S 0.00 1.00 22.2
4 CD8þVb1þ C T C16orf89 NS 1 ENST00000350219 R83K 0.64 0.07 19.5
4 CD8þVb1þ T C EPRS NS 20 ENST00000366923 N982S 0.58 0.00 19.2
4 CD8þVb1þ TA T TOPAZ1 FS 2 ENST00000309765 N628fs NA NA 14.5
4 CD8þVb1þ C T MAST1 NS 13 ENST00000251472 R496C 0.01 1.00 10.3
4 CD8þVb1þ C G CDYL NS 4 ENST00000328908 A190G 0.34 0.41 8.1
AA, amino acid; FS, frameshift; NS, non-synonymous; ref, reference base; SIFT, SIFT score for the non-synonymous mutation (0-deleritorious, 1-tolerated); SSA, splice-site acceptor; STOP, stop codon
introduced; Polyphen, polyphen-2 score for the non-synonymous mutation (0-benign, 1-damaging); var, variant base.
CD4þ and CD8þ cells from 23 patients and 7 healthy controls were sequenced with the immunogene panel of 986 genes, and 3 patients’ sorted CD8þ Vb clones underwent exome sequencing.
Immunogene panel sequencing detected mutations in 4 patients and 1 healthy control, whereas exome sequencing detected several mutations in each expanded clone. Polyphen and SIFT scores were
determined for the transcript with the most deleterious prediction value. SIFT scores o0.05 and Polyphen-2 scores 40.85 were considered probably damaging (shaded with grey). . *)
50-GGCTGACCCCAGC-30 **) Prediction algorithms did not return scores because the mutation resided outside the consensus coding sequence set. ***) PADI4 mutation site coverage was low (10–12 )
in exome sequencing and thus did not permit high-conﬁdence mutation detection.
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Figure 3 | Somatic mutations occur in expanded CD8þ T-cell clones that persist during follow-up. (a) The ﬁgure shows the CD8þ clonal architecture
of patient 1, on the basis of TCRB sequencing and V-J genes. The Vb13.1þ population detected by ﬂow cytometry corresponded to clones using
TCRBV06-05, 06-06, or 06-09 genes. (b) TCRB sequencing showed that patient 1 harboured two very large CD8þ T-cell clones. The two expanded
clones of patient 1 persisted at a similar level during follow-up. The amino-acid TCRB sequences and the V genes of these unique clones are shown
in the ﬁgure. (c) Amplicon sequencing of FACS-sorted cell fractions conﬁrmed the identiﬁed mutations. The table presents the VAFs in each cell fraction.
(d) The clonal architecture of patient 2’s CD8þ pool as shown via V and J genes. Clones using TCRBV09-01 correspond to Vb1þ antibody in ﬂow
cytometry. (e) Similarly presented TCRB sequencing results of ﬂow-sorted Vb1þ cells. When examining unique clones (‘unique’ deﬁned by a unique
nucleotide sequence) the largest clone composed 73% of all CD8þ Vb1þ cells. (f) Patient 2 harboured several unique CD8þ T-cell clones at diagnosis.
The TCRBV09-01 clone, in which mutations were observed, increased slightly during the follow-up. Amino-acid sequences derived from these unique
clones are shown. The clone using TCRBV09-01 in this panel had the exact same nucleotide TCRB sequence as the largest clone in sorted Vb1þ cells.
(g) Amplicon sequencing results on FACS-sorted cells show the VAFs in each cell fraction. The low (o1%) VAFs found in CD4þ and Vb13.6þ cells are
considered sorting impurities, and thus the mutations in patient 2 occur exclusively in CD8þVb1þ cells. The mutation VAFs in CD8þVb1þ cells
correspond well with the TCRBV09-01 clone size in sorted cells (h) The clonal landscape of CD8þ cells from patient 3. Clones using TCRBV04-03 gene
correspond to Vb7.2 usage in ﬂow cytometry. (i) Patient 3 harboured a very large CD8þ T-cell clone at diagnosis, which persisted at a similar level during
follow-up. (j) Amplicon sequencing of ﬂow-sorted cell populations showed that the mutations detected in exome sequencing exist only in Vb7.2 CD8þ
T cells and not in other T cells.
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Patient 3 was a 44-year-old male with seropositive erosive RA.
Flow cytometry identiﬁed a large CD8þVb7.2þ population
composing 55% of all CD8þ T cells (Supplementary Fig. 9).
TCRB sequencing revealed a CD8þ T-cell clone at 51% that
corresponded to the ﬂow cytometry result (Fig. 3h), and the clone
remained stable during the follow-up (Fig. 3i) Immunogene panel
sequencing did not reveal any mutations, but the mutations
identiﬁed by exome sequencing in proliferation-associated genes
(SMARCAD1, PLRG1, ADCY10) were restricted to the CD8þ
Vb7.2þ population (Fig. 3j).
Patient 4 was a 74-year-old female with seronegative disease.
Flow cytometry analysis showed a CD8þVb1 population at 44%,
and the population harboured mutations in nine different genes
(full list of affected genes in Fig. 2a, Table 2, and Supplementary
Table 6). Patient 5 was a 59-year-old woman with seropositive
RA, asthma and non-compaction cardiomyopathy. Flow cyto-
metry did not detect large CD8þ T-cell populations expressing a
certain Vb; however, deep TCRB sequencing detected a clone
composing 29% of all CD8þ cells (Table 1). Her CD8þ cells
harboured one mutation in CLEC10A gene at 10% VAF (Fig. 2a).
In addition, one healthy control (HC5, a 65-year-old female)
harboured a somatic mutation in CD8þ cells at a VAF of 13.9%
(CLU, Fig. 2a). Deep TCRB sequencing revealed that the largest
CD8þ clone composed 25% of CD8þ . No other somatic
mutations were identiﬁed in the healthy controls despite the
higher median target coverage in healthy controls compared with
that in RA patients (Supplementary Table 5).
RNA sequencing conﬁrms the somatic mutations. RNA
sequencing was performed to assess the expression levels of the
mutated genes both in the expanded Vb population and in
polyclonal CD8þ cells from the same patient (patients 1–3,
Fig. 4a). All somatic mutations with sufﬁciently high expression
were conﬁrmed from the RNA sequencing data (Fig. 4a).
Paired analysis of Vb-antibody-positive and -negative fractions
revealed a proliferation and survival associated signature in the
expanded Vb populations (Fig. 4b). Functional annotation using
RefSeq summaries indicated a shared functional state that
supports survival and enhanced proliferation in the cell
fractions containing the expanded clones. When each mutation-
harbouring Vb-stained cell population was analysed alone,
several immunologically relevant characteristics were assigned
to each mutation-bearing fraction (Fig. 4b). Interestingly, the
PADI4 mutation resulted in dramatic downregulation of mRNA
transcripts in patient 1 with the A359T mutation in his CD8þ
Vb13.1þ cell population.
The mutated clones show an effector-memory phenotype.
We studied the phenotype of the mutation-harbouring T-cell
populations with multicolour-ﬂow cytometry, using follow-up
samples collected during ongoing antirheumatic therapy. In
patients 1 and 3, the CD8þ populations expressing the
speciﬁc Vb (13.1 and 7.2, respectively) showed an effector-
memory (CCR7-CD45RA-) phenotype, whereas the polyclonal
CD8þ cells not expressing the same Vb and CD4þ cells
showed a balanced T-cell distribution (Fig. 5a,b). In patient 2,
the CD8þVb1þ population had a terminally differentiated
effector-memory phenotype (CCR7-CD45RAþ ; Fig. 5c).
Cytomegalovirus (CMV)-reactive T-cell clones commonly
occur in elderly individuals and are related to the increased
clonality of CD8þ T cells23. Thus, we compared all RA CD8þ
clones exceeding 1% against published viral-speciﬁc TCRB
sequences (listed in the Supplementary Information), but only a
few TCRs have previously been reported to be virus speciﬁc
(Supplementary Table 8). The TCRB sequences of major CD8þ
clones in patients harbouring mutated cells were not among the
published
viral-speciﬁc TCRB sequences. Additionally, we tested CMV
reactivity in patients 1 and 2 with a NLV-peptide-speciﬁc
pentamer, and only a minor proportion of CD8þ T cells were
CMV NLV-epitope speciﬁc (Supplementary Fig. 10).
The conﬁrmed mutations are not reproduced in other RA
patients. The somatic mutations identiﬁed by the immunogene
panel in patients 1 and 2 (PADI4, PROM1, C5, IRF1, SLAMF6
and SEC14L3) were screened in 82 RA patients with targeted
amplicon sequencing (coverage 4,000–79,000 , sensitivity 0.5%
(ref. 14)). For most patients, both CD8þ and CD4þ -enriched
fractions were used in the analysis. No coding region mutations
were detected within the amplicons covering the mutation sites.
Finally, because some RA patients showed marked STAT3
phosphorylation in phosphoﬂow analyses (Supplementary Fig. 11),
we examined all 82 patients for previously described somatic
variants in exon 21 of STAT3. Amplicon sequencing coverage
reached 4,800–110,000, but no mutations in STAT3 were
identiﬁed. In conclusion, none of the screened mutations occur-
red in other patients.
Discussion
This study presents the novel discovery of somatic mutations in
both immune- and proliferation-associated genes in the CD8þ
T cells of patients with newly diagnosed, untreated RA. Several
recent reports have shown that somatic mutations originating
from haematopoietic precursor cells occur in blood cells of
the healthy elderly (clonal haematopoiesis) and that the
prevalence of clonal haematopoiesis increases with age. Many of
these mutations occur recurrently in myeloid malignancies,
and their presence in healthy individuals increases the risk
of haematological cancers3–6. Interestingly, somatic clonal
mosaicism in blood- and buccal cells has also been shown
to associate with solid tumours24. To underscore the
developmentally late emergence of the mutations in CD8þ
effector T cells, we used CD4þ cells as the comparator in our
study. This method excluded mutations that had already arisen in
precursor cells. To our knowledge, this is the ﬁrst study showing
the emergence of somatic mutations in effector T cells in patients
with a non-malignant autoimmune process.
Somatic mutations were identiﬁed in genes that were expressed
in CD8þ lymphocytes and that are known regulators of
immunity (such as IRF1 and SLAMF6) and cell proliferation
(PLRG1). Notably, no mutations were detected in CD4þ cells,
and only one somatic mutation was identiﬁed in 1 out of the
20 healthy controls.
In 16% of the cases, the mutations were either frameshift-
or nonsense-mutations, and thus functional consequences
were apparent. To evaluate the effects of the identiﬁed
non-synonymous mutations on the structure and function of
the affected proteins, we used two separate bioinformatics tools
(Polyphen-2 and SIFT), and both indicated likely deleterious
effects in 32% of the non-synonymous cases. RNA-sequencing
results demonstrated that many of the mutated genes were highly
expressed in CD8þ cells, and thus mutations in these genes have
the capacity to modulate cellular functionality. Interestingly,
the RNA sequencing data also revealed a survival/proliferation-
associated signature in the ﬂow-sorted cells in which the
mutations were located. These data together suggested that the
expanded fractions differ from the highly polyclonal background
pool. The differences may be both related and unrelated to the
identiﬁed somatic mutations. More research is warranted to
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understand in detail the biological consequences of the identiﬁed
somatic mutations.
Previous studies with smaller cohorts have reported clonal
CD8þ T-cell expansions in RA patients’ blood samples25–27. In
contrast to these studies, we studied the clonal architecture of
CD8þ T cells by NGS TCRB sequencing. TCRB sequencing
identiﬁed large clonal expansions in both RA patients as well as in
healthy controls, and no difference in clonality was found
between the two groups. This result was not unexpected because
large CD8þ T-cell clones are not uncommon in the elderly28,29,
and the median ages of our patient and control groups were
essentially identical. Further, our results showed that age was
positively correlated with the clonality index (older individuals
harboured more large clones than younger people), a result in line
with ﬁndings from studies showing that age is associated with
decreased TCR diversity30.
CD8þ T cells display more clonal characteristics than CD4þ
cells do (as shown by our ﬂow cytometry data, and sequenced
by Qi et al.30). Vigorous proliferation involving repeated
DNA-replication cycles predisposes the clone to an increased
risk of mutagenesis. Larger cell clones also enable detection of
mutations with larger VAFs, thus technically facilitating
identiﬁcation of somatic variants. Despite the similar CD8þ
clonality in the RA patients and controls, somatic mutations were
observed in 5 (out of 25) RA patients and only in 1 (out of 20)
healthy control. We conclude that the chronic inﬂammatory state
in RA9 may facilitate the acquisition of somatic mutations,
and thus, we hypothesize that somatic mutations may also occur
in other inﬂammatory conditions.
Possible TCR target antigens in RA have been studied
intensively. Whereas CD4þ cells have received much attention,
CD8þ cells have mainly been studied as a potential link between
autoimmunity and viral infections. Virus-speciﬁc (Epstein-Barr
virus (EBV), CMV, inﬂuenza) CD8þ T-cell enrichment has been
reported in RA patients’ synovial ﬂuid31, and EBV has been
reported as a possible target antigen for expanded T cells in RA
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Figure 4 | Expression levels of mutated genes and a survival signature in mutation-harbouring cells. CD8þ cells from 3 healthy controls as well as
mutation-harbouring CD8þVbþ and polyclonal CD8þ T cells from patients 1, 2, and 3 were sorted with ﬂow cytometry. (a) RNA sequencing was
performed on the sorted fractions. The normalized mean expression levels calculated from the healthy CD8þ T cells and from the patients’ polyclonal
CD8þ fractions are presented in the control expression column. In the following columns, each sorted population containing the mutated clone is
presented individually. (b) The upper panel presents proliferation/survival -associated genes identiﬁed by paired analysis of the mutation-harbouring cell
populations and their polyclonal background populations. Immunologically important transcripts are presented in the lower panel. The transcripts were
ﬁltered with threshold expression level 0, FC41,5 oro 1,5 and Po0.01. Abbreviations: Aa, amino acid; fs, frameshift; *, stop-codon gained; -, splice-site
acceptor mutation. The function of the gene was retrieved from the RefSeq database and noll-hypothesis was tested using ANOVA in the Qlucore software
package.
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patients32. Virus-speciﬁc clones may display cross-reactivity
towards autoantigens33, thus enabling interaction with the
autoimmune inﬂammation process. Because the antigen target
of the expanded clones in our study is unknown the
interpretation of the results is limited. None of the largest
(45%) CD8þ clones were among the previously published
virus-speciﬁc TCRB sequences, but this approach does not rule
out the possibility that the clones might be virus-speciﬁc. Future
studies are needed to assess whether common viral- or auto-
antigens are targets of these clones. However, TCRs show
remarkable binding plasticity and cross-reactivity between allo-
antigens and auto-antigens34,35, thus enabling autoreactive
properties independent of their primary antigen target.
We identiﬁed somatic mutations in memory-type36 CD8þ
T cells. In two patients, the mutations were discovered in clones
without CD45RA expression (effector-memory cells), and in one
patient the mutated clone was CD45RA-positive (terminally
differentiated effector-memory phenotype cells). Both phenotypes
represent cells that have encountered their antigen, proliferated,
and participated in a cytotoxic response. After the antigen
encounter, the clones failed to shrink and persisted in these
patients. We hypothesize that this ﬁnding may be due, in part, to
the somatic mutations that the cells have acquired during the
proliferation process (Fig. 6).
Future studies are needed to elucidate whether the mutation-
harbouring CD8þ T-cell clones truly participate in the
pathogenesis of an autoimmune disease, or whether they are like
‘scars’ in the genome after vigorous antigen-driven proliferation.
Even though the role of CD8þ cells in RA remains less well-
established than the role of CD4þ T cells, there is a growing
body of evidence supporting the role of CD8þ T cells as
regulators of autoimmune arthritis37. Interestingly, the genes
found to be mutated in our patient material (such as SLAMF6
(ref. 38), PADI4 (ref. 39) and IRF1 (ref. 40)) have been shown to
regulate autoimmunity and to be associated with the initiation
and progression of RA (PADI4 and IRF1).
Our study highlights novel putative mechanistic similarities
between autoimmunity and cancer: somatic mutations in disease-
associated cells. The occurrence of mutations in terminally
differentiated T cells may discriminate a benign disorder from a
malignant transformation (such as leukaemia or lymphoma),
because terminally differentiated effector-memory cells have
limited proliferation potential. These data lay the groundwork
for future studies seeking to understand the role of somatic
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Figure 5 | Expanded CD8þ T-cell clones are effector-memory T cells. Multicolour-ﬂow cytometry was used to determine the phenotype of patients’
T cells in samples taken during the follow-up. CCR7 and CD45RA were used to determine whether the cells were central memory (CM), naive,
effector-memory (EM) or terminal effector-memory RA-positive (TEMRA) cells. (a) The CD8þ Vb13.1þ cells of patient 1 comprise 50% of all CD8þ
T cells. The phenotype of CD8þVb13.1þ , other CD8þ , and CD4þ T cells are displayed in separate plots. (b) The phenotype of CD8þVb7.2þ ,
other CD8þ , and CD4þ T cells of patient 3 are displayed in separate plots. (c) The phenotype of expanded CD8þVb1þ , other CD8þ , and CD4þ
T cells of patient 2 are presented in separate plots.
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mutations in autoimmune diseases and other non-malignant
disorders.
Methods
Study design. This is a prospective study of newly diagnosed RA patients
approved by the Helsinki University Hospital Ethics Committee. Patients were
enrolled to the study in the Department of Rheumatology (Helsinki University
Hospital, Finland) and all newly diagnosed patients referred to our clinic between
2012–2013 fulﬁlling the ACR & EULAR 2010 classiﬁcation criteria were aimed to
be recruited. Written informed consents were required from all participants and
the Declaration of Helsinki was followed.
Patient samples. Routine laboratory and clinical parameters were recorded
from all participating patients. Clinical parameters included the total amount of
tender and swollen joints, Disease Activity Score in 28 joints, Health Assessment
Questionnaire and the patient’s global assessment of disease activity on visual
analogue scale, and the duration of symptoms before diagnosis. Peripheral-blood
samples (30ml EDTA blood) were obtained directly after diagnosis and before
initiating treatment. For immunogene- and TCRB-sequencing, 20 healthy blood
donor buffy coats (provided by the Histocompatibility Testing Laboratory, Finnish
Red Cross Blood Service) served as controls.
Sample preparation. Peripheral-blood mononuclear cells (PBMCs) were
separated from EDTA blood using Ficoll gradient separation (Ficoll-Paque PLUS,
GE Healthcare, cat. no 17-1440-03). CD4þ and CD8þ cells were separated with
magnetic bead sorting using positive selection for both fractions (AutoMACS,
Miltenyi Biotec). Purities of the sorted fractions were conﬁrmed with ﬂow
cytometry (FACSAria II, Becton Dickinson) and the gating strategy for all PBMC
analysis is presented in Supplementary Fig. 12.
Clonality analysis with ﬂow cytometry. Peripheral whole-blood samples were
stained for lymphocyte clonality analysis with anti-CD3 (SK7, BD, cat. no 345767),
anti-CD4 (SK3, BD, cat. no 345770), and anti-CD8 (SK-1, BD, cat. no 335822) and
a panel of T-cell receptor b variable chain (TCR Vb) antibodies (IOTest Beta Mark
TCR V kit, Beckman Coulter Immunotech, cat. no IM3497), which recognize
B70–80% of human TCR b V regions. All ﬂuorochrome-conjugated antibodies
were used according to the manufacturer’s instructions. Similarly, all b variable
chain (TCR Vb) antibodies were used according to the manufacturer’s instructions
and all antibody information is included in the kit user manual and also in the
Supplementary Fig. 13. After staining, red blood cells were lysed with BD FACS
Lysing Solution (Becton Dickinson Biosciences, cat. no 349202) and re-suspended
to phosphate-buffered saline (PBS) with 2mM EDTA. Samples were analysed with
FACSAria II (Becton Dickinson) and FACSDiva software (Becton Dickinson). The
gating strategy for all whole-blood stainings is presented in the Supplementary
Fig. 13.
Flow-assisted cell sorting. Cell sorting was performed from PBMC fractions
using FACSAria II (Becton Dickinson) or Sony SH800 (Sony Biotechnology Inc.).
For sorting, PBMC cells were stained with anti-CD3 (SK7, BD, cat. no 345767 or
557851), anti-CD4 (SK3, BD, cat. no 345770), anti-CD8 (SK-1, BD, cat. no 335822
or 345772) and the appropriate anti-Vb antibody. Purities of the sorted cell
fractions were controlled with ﬂow cytometry, and the purities were nearly 100%.
Phenotyping and CMV-pentamer staining. For phenotyping analyses, PBMCs
were stained with anti-CD3 (SK7, BD, cat. no 345767), anti-CD4 (SK3, BD, cat.
no 345770), anti-CD8 (SK1, BD, cat. no 335822), anti-CCR7 (150503, BD, cat. no
562555), anti-CD45RA (HI100, BD, cat. no 560673) and the appropriate Vb
antibody were used. For CMV-pentamer staining, cells were labelled with iTAg
MHC pentamer (HLA-A-0201, NLVPMVATV, Proimmune, PE conjugate) and
anti-CD3, CD8, and CD4. Samples were analysed with FACSVerse (Becton
Dickinson) and FlowJo software.
Phosphospeciﬁc ﬂow cytometry. For phosphospeciﬁc ﬂow cytometry, 100 ml
aliquots of whole-blood were supplemented with 5 ml anti-CD4 (FITC, SK3) and
3 ml anti-CD8 (SK1, BD). After a 15-min incubation at þ 37 C, ﬁxation, red-cell
lysis (1 Lyse/Fix Buffer, BD) and permeablization followed (100 ml 1
PhosFlow Perm/Wash Buffer I, BD). The phosphorylated intracellular targets
were labelled using 5 ml anti-pSTAT3 (pTyr705)-PE (4/p-STAT3, BD), 5 ml
anti-pSTAT3(pSer727)-AlexaFluor647 (49/p-STAT3, BD), 5 ml polyclonal rabbit
anti-pJAK1(pTyr1022/1023, 1:10 dilution in PBS, Merck), 7 ml anti-pJAK2
(pTyr1007/1008, Santa Cruz Biotechnology), 7 ml anti-pJAK3(pTyr980, Santa
Cruz Biotechnology) and 7 ml anti-SHP1(pTyr536, 1:10 dilution in PBS, Abcam).
Anti-CD3 (SK7) was also added following permeabilization. F(ab0)2 donkey
anti-rabbit IgG (BD) was used as ﬂuorescent secondary antibody in 40-min
incubation as PE-conjugate for pJAK1 (2ml), pJAK2 (5 ml) and pSHP1 (2ml) and
PerCP-conjugate for pJAK3 (2ml). The samples were kept on ice and analysed
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Figure 6 | Hypothesis for the accumulation of somatic mutations. Mature Tcells undergo thymic selection, and during the expansion phase after antigen
stimulation, mutation(s) occur (1st mutation). When the cell population continues to grow, additional mutations may arise in the same clone, thereby
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within 4 h with FACSCantoII ﬂow cytometer and analysed with FACSDiva
software (BD) as described previously41,42. Each patient sample was compared to a
healthy control sample taken during the same week, which was used to determine
gating for positive and negative populations: the histogram of a healthy control
subject’s sample was set not to cover more than 5% of the cells of the population,
and this gate was copied to patient samples. The gating strategy for
phosphorylation analysis is presented in the Supplementary Fig. 14.
DNA extraction. DNA was extracted from CD4- and CD8-enriched samples or
from the PBMC fraction with Nucleospin Tissue DNA extraction kit (Machery
Nagel, cat. no 740952.250) or Nucleospin Tissue XS kit (Machery Nagel, cat. no
740901.5) according to the manufacturer’s instructions. DNA concentration was
measured with Qubit 2.0 ﬂuorometer (Life Technologies) using the Qubit HS or BR
dsDNA Assay Kit (Life Technologies, Cat. Nos Q32854 and Q32853).
TCRB CDR3 deep sequencing. To conﬁrm the clonality screening results
obtained via ﬂow cytometry, TCRB deep sequencing was performed from 65
patients, accompanied by sequencing of 20 healthy controls (whose samples also
underwent immunogene panel sequencing). Genomic DNA was used in all cases.
Sequencing and data analysis were conducted as previously described with
ImmunoSEQ assay by Adaptive Biotechnologies Corp43,44. Only productive TCR
sequences were included in all analyses in this report.
Clonality was calculated according to the formula:
Clonality ¼ 1 
PN
i¼1 pilog2ðpiÞ
log2ðNÞ
ð1Þ
where pi is the proportional abundance of the rearrangement i, and N is the total
number of rearrangements. The numerator of the equation is Shannon’s entropy.
TCR repertoire overlap between two samples was calculated with the following
formula:
Overlap ¼
Pn
i ai þ bi
AþB ð2Þ
in which ai is the template count of clone i in sample A, bi the template count of
clone i in sample B, A the total number of templates in sample A, and B the total
number of templates in sample B.
Immunopanel sequencing. A list of 986 genes related to immunity and cancer was
created (Supplementary Table 5), including genes in the annotated InnateDB
database (http://www.innatedb.ca/). Additional potentially interesting targets
such as JAK-STAT pathway-related genes were compiled from different
publications45–49. The probes were designed based on the genomic coordinates for
the coding parts and surrounding untranslated regions of the genes by the
Nimblegen SeqCap EZ Developer system.
Two different DNA library preparation kits were used in this study: NEBNext
(New England BioLabs, cat. no E6040L) and ThruPLEX DNA-seq (Rubicon
Genomics, cat. no R400407). For the NEBNext kit, the DNA libraries were
prepared from 1–3 mg DNA according to NEBNext DNA Sample Prep Master Mix
Set 1 (New England BioLabs) manual with minor modiﬁcations: (1) 1 ml of the
25mM adaptor was used in ligation instead of 10 ml of 15mM adaptor. Illumina
Index PE adaptor oligo mix (from primers 50-GATCGGAAGAGCACACGTCT-30
and 50-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-30) was used in
ligation. Both oligos were custom ordered from Sigma Aldrich (St Louis). (2) After
each consecutive library preparation step the library was puriﬁed with Agencourt
AMPure XP -beads (Beckman Coulter, cat. no A63881). (3) For each library 15 ng
of ligated library was used for pre-capture PCR in ﬁve parallel reactions. Twelve
ampliﬁcation cycles were used. (4) The initialization step in the ampliﬁcation was
2min instead of 30 s and the denaturation step was 20 s instead of 30 s. (5) Illumina
PCR Primer InPE 1.0 (50-AATGATACGGCGACCACCGAGATCTACACTCTTT
CCCTACACGACGCTCTTCCGATCT-30) was used as a forward primer. For each
library different, indexed, long reverse primer was used. Each indexed, long reverse
primer was custom made and merged from the Illumina PCR Primer InPE 2.0
(50-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-30) and Illumina
TruSeq Small RNA index primer (50-CAAGCAGAAGACGGCATACGAGATNN
NNNNGTGACTGGAGTTC-30 , NNNNNN being the selected small RNA index).
The merged long reverse primer template was 50-CAAGCAGAAGACGGCATAC
GAGATNNNNNN GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-30 in
which the NNNNNN sequence was replaced with selected index. Using these long
reverse primers decreased the cycles needed in ampliﬁcation from 19 to 12. All
primers were custom ordered from Sigma Aldrich (5). Sufﬁcient amount of library
was produced, hence the LM-PCR step in the NimbleGen protocol was excluded.
Library quantiﬁcation was performed using 2100 Bioanalyzer High sensitivity kit
(Agilent, Santa Clara, CA, USA, cat. no 5067-4626).
Target region captures were performed according to NimbleGen SeqCap EZ
Exome Library SR User’s Guide with minor modiﬁcations. NimbleGen captures
were performed according to NimbleGen SeqCap EZ Exome Library SR User’s
Guide with the following exceptions. (1) An aliquot of 10 ml of 100 mM Illumina
PCR Primer InPE 1.0, MPLEX_blockAdapter2.0 (50-GTGACTGGAGTTCAGACG
TGTGCTCTTCCGATCT-30) and MPLEX_blockTail2.0 (50-CAAGCAGAAGACG
GCATACGAGAT-30) was used for blocking in each library. (2) An aliquot of 4 ml
of the captured library was used in ﬁve parallel 50 ml ampliﬁcation reactions. An
aliquot of 1 ml of 100mM NimbleGen PE-POST1 and PE-POST2 primers were used
in each reaction. Twelve cycles were used.
For the ThruPLEX library preparation, 100 ng of gDNA of each was fragmented
with Episonic Multi-Functional Bioprocessor 1100 (Epigentek Group Inc.,
Farmingdale, NY, USA) to mean fragment size of 300 bps,and 50 ng of fragmented
DNA (fragmenting controlled with fragment analysis) was used in the following
procedures. The libraries were processed according to ThruPLEX DNA-seq library
preparation kit (Rubicon Genomics, Ann Arbor, MI, USA). Five ampliﬁcation
cycles were used. The libraries were quantitated with 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). The captures were performed according to
Rubicon Genomics’ protocol for Exome Capture of ThruPLEX Libraries with
Roche NimbleGen SeqCap EZ Library (Rubicon Genomics, Ann Arbor, MI, USA).
Roche Nimblegen custom capture probes were used to perform the capture. After
hybridization the captures were performed according to NimbleGen SeqCap EZ
Exome Library SR User’s Guide.
All ampliﬁed libraries (pre-capture preparation with NEBNext or ThruPLEX)
were puriﬁed with Agencourt AMPure XP beads (cat. no A63881) and quantiﬁed
for sequencing using 2100 Bioanalyzer High sensitivity kit (cat. no 5067-4626).
Sequencing was performed with the Illumina HiSeq system. Sequencing was done
from both CD8þ and CD4þ cells of each patient.
Bioinformatic analyses for somatic variant detection. The principle of
the somatic variant-calling pipeline has been previously described13.
SeqPrep 0.4.5 was used to merge raw Illumina reads, and resulting paired
reads were trimmed of B blocks in the quality scores from the end of the read.
Trimmed readso36 basepairs were removed. Read-alignment was performed with
Burrows–Wheeler Aligner version 0.6.2 (ref. 50) against the human genome
GRCh37 reference-genome. Reads mapping to multiple genomic positions were
removed. GATK Indel Realignment version 2.2–16 was used to reﬁne the read
alignment. After aligning, potential PCR duplicates were removed with Picard
MarkDuplicates version 1.90.
VarScan2 somatic algorithm version 2.3.2 (ref. 51) was used to call high-
conﬁdence somatic mutations for each patient. The following parameters were
used: strand-ﬁlter 1, min-coverage-normal 8, min-coverage-tumor 6, somatic
P value 1, normal-purity 1 and min-var-freq 0.05. Mutations were annotated using
SnpEff version 4.0 (ref. 52) with the Ensembl v68 annotation database53. To ﬁlter
out misclassiﬁed germline variants, the variants classiﬁed as common population
variants in Single Nucleotide Polymorphisms database (dbSNP, build ID 130) were
removed.
CD8þ cells included the expanded clones of interest, whereas CD4þ cells
served as a germline control and was used to ﬁlter individual germline variants
when the data were analysed. The bioinformatics pipeline was also run using
CD8þ cells as germline control, but no somatic variants were conﬁrmed in
subsequent sequencing with the deep Amplicon method in CD4þ cells.
Amplicon sequencing. Targeted, deep amplicon sequencing (Illumina) is a
PCR-based method with coverage up to over 100,000 and a sensitivity of 0.5%
VAF14. Amplicon sequencing was used to validate candidate mutations found in
the immunopanel sequencing and to screen mutations from the whole patient
cohort. Amplicon sequencing of selected genes was performed as described
previously14,54, and the primers used are listed in Supplementary Table 9.
The amplicon primers were designed to cover the exon that harboured the
identiﬁed mutation. Either 1-step or 2-step PCR was used. The 1-step PCR was
performed in a volume of 20 ml containing 10 ng of sample DNA, 10 ml of 2
Phusion High-Fidelity PCR Master Mix (Thermo Fisher Scientiﬁc, cat. no F531L),
0.025 mM of each locus-speciﬁc primer, 0.5 mM of index primer 1 (P5) and
0.5 mM of index primer 2 (P7), supplemented with water to the ﬁnal volume
(Sigma-Aldrich). In this reaction, the locus-speciﬁc primers are present in limiting
quantities. Adaptor primers amplify these products further. For the 2-step PCR
protocol, the ﬁrst PCR was done in a volume of 20 ml containing 10 ng of sample
DNA, 10ml of 2 Phusion High-Fidelity PCR Master Mix and 0.375 mM of each
locus-speciﬁc primer, supplemented with water to the ﬁnal volume. The second
PCR was done in a volume of 20 ml containing 1 ml of the ampliﬁed product from
the ﬁrst PCR, 10ml of 2 Phusion High-Fidelity PCR Master Mix, 0.375mM of
index primer 1 and 0.375 mM of index primer 2.
DNA Engine Tetrad 2 (Bio-Rad Laboratories) or G-Storm GS4 (Somerton)
thermal cyclers were used to cycle the sample according to the program: initial
denaturation at 98 C 30 s, 30 cycles at 98 C for 10 s, at 59–63 C for 30 s, and at
72 C for 15 s, and the ﬁnal extension at 72 C for 10min. If a second PCR cycle
was used (in 2-step PCR protocols), the second PCR was done according to the
program: initial denaturation at 98 C 30 s, eight cycles at 98 C for 10 s, at 65 C
for 30 s, and at 72 C for 20 s, and the ﬁnal extension at 72 C for 5min.
The ampliﬁed samples were pooled together without exact quantiﬁcation and
the pool was puriﬁed with Agencourt AMPure XP beads (Beckman Coulter, cat. no
A63881) twice using 0.8 volume of beads compared to the sample pool volume,
which removes effectively primer dimers from the sample pool. Agilent 2100
Bioanalyzer (Agilent Genomics) was used to quantify ampliﬁcation performance
and yield of the puriﬁed sample pools. Sample pools were sequenced with Illumina
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MiSeq System using Illumina MiSeq Reagent Kit v2500 cycles kit (Illumina, cat. no
MS-102-2003).
Sequencing reads were aligned to the human hg19 genome with Bowtie2.
GATK IndelRealigner was used for local realignment near indels. Low-quality
reads were also aligned to the genome, but quality scores were used to exclude error
bases in further analysis. All variant alleles with count 45 and VAF of over 0.5%
were called. A speciﬁc frequency ratio was calculated by dividing the ratio of
variant calls/number of all the bases (at a position) by the ratio of variant allele
quality sum/quality sum of all bases. This ratio was used to ﬁlter out false positive
variants: variants with a frequency ratio o0.8 were excluded. In this study, the
mutation was considered to be true if it was present in the sequenced sample with a
similar VAF as reported by exome/immunogene panel sequencing, and if the
variant was absent from the control sample from the same patient.
Exome sequencing. The expanded CD8þVb clones of patients 1, 2 and 3 were
sorted with FACSAria II, and underwent exome (50 ng of DNA) sequencing with
Nextera Rapid Exome Kit (Illumina, cat. no FC-140-1083). CD4þ cells served as
germline control. The exome sequencing and bioinformatics pipeline to discover
somatic variants were done as described previously13, with the same analysis
pipeline as with immunogene panel data.
RNA sequencing. RNA was isolated using Qiagen miRNeasy micro kit (cat. no
217084) and SMART-Seq v4 Ultra Low Input RNA Kit (cat. no. 634890) for
Sequencing was utilized to produce cDNA libraries. cDNA fragmentation and
sequencing adaptor tagging war performed using Illumina Nextera XT kit
(FC-131-1096). Sequence data correction, quality trimming and read length
ﬁltering were performed with Trimmomatics using the following settings:
leading: 3, trailing: 3, sliding window: 4:15 and minlen: 36. The gap-aware STAR
aligner was used to perform the spliced alignment of ﬁnal clean paired-end reads
against the human reference genome (Ensembl GRCh38) with the guidance of the
EnsEMBL reference gene models (EnsEMBL v80). The default alignment and
indexing settings (2-pass per-sample) were used, except that the overhang on each
side of the splice junctions was set to 99. Picard tools were used to sort the reads
and to mark the reads. The reads were then assigned to genomic features using
SubRead. Default parameters were used in the feature summations except that
reads were allowed to be assigned to overlapping genome features. Quality control
analysis was performed using the RNA-SeQC and FASTQC with default settings
and using genome annotation information downloaded from EnsEMBL (v80). The
obtained BAM ﬁles were normalized and the data was explored and visualized
using the Qlucore Omics Explorer 3.2(Qlucore AB, Lund, Sweden).
HLA typing method. All the samples were typed at the Histocompatibility Testing
Laboratory, Finnish Red Cross Blood Service accredited by European
Federation for Immunogenetics. The HLA speciﬁcities were reported based
on the current World Health Organization (WHO) nomenclature for the HLA
system.
The typing for HLA-A, -B, -C and -DRB1 loci was performed using the
Luminex bead array technology together with sequence-speciﬁc oligonucleotide
probes (Commercial LabType kits RSSO1A, RSSO1B, RSSO1C, RSSO2B1, One
Lambda, Los Angeles, CA). The bead array data were interpreted according to the
manufacturer’s recommendations using the HLA Fusion software 3.2 (One
Lambda).
A proportion of samples was further typed by Sanger sequencing method to
obtain higher resolution for the HLA type (Commercial AlleleSEQR kits 08K60-06,
08K61-06, 08K62-06, 08K63-06, GenDx, Utrecht, Netherlands). The sequencing
data were analysed using the SBTengine software 3.9.0.2563 (GenDx).
Shared epitope alleles. Known HLA susceptibility loci, the shared epitope alleles,
were deﬁned in our study as HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*10 and
HLA-DRB1*14:02 (ref. 15).
Statistical analysis. Bioinformatic methods are described in other sections.
Statistical analyses were performed using Prism 6 for Mac OS X, Version 6.0, and R
(version 3.3.1). In all analysis Po0.05 were considered as statistically signiﬁcant.
Normality of the data was inspected graphically and tested with Shapiro–Wilk test.
If one of the studied groups did not follow normal distribution, or if the group
sample size was small, nonparametric statistical tests were performed. Statistical
methods comprised of Mann–Whitney test, Fisher’s exact test, linear regression
and Spearman correlation, which were used as indicated in ﬁgure legends.
Data availability. The sequence data that support the ﬁndings of this study are
available in ImmuneAccess with the identiﬁer https://doi.org/10.21417/B76C7W.
Other sequence data (immunogene panel, exome and RNA sequencing raw data)
are only available from the corresponding author upon request, owing to regula-
tions pertaining to the authors ethics permit and deposition of these data in public
repositories.
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